This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

IBio Adds To IBioModulator Portfolio And Product Pipeline

NEWARK, Del., March 13, 2013 /PRNewswire/ -- iBio, Inc. (NYSE MKT: IBIO) today announced notification from the U.S. Patent and Trademark Office that a new patent in the Company's iBioModulatorâ„¢ portfolio will issue on March 26, 2013. The new patent, number 8,404,252 entitled " Yersinia pestis Antigens, Vaccine Compositions and Related Methods," includes claims covering plague antigens fused to the Company's thermostable immunomodulator -- iBioModulator â„¢-- protein, as well as vaccine compositions and a method for producing a protective immune response to the antigen.  The invention was developed by scientists at the Fraunhofer USA Center for Molecular Biotechnology (FhCMB), iBio's research collaborator and is owned by iBio.

(Logo:  http://photos.prnewswire.com/prnh/20120419/NY91086LOGO )

Plague is considered a potential bioterrorism weapon.  There is no plague vaccine currently approved for use in the U.S.  Although killed whole-cell plague vaccines have been reported to protect against bubonic plague in animal models, such vaccines were not effective against pneumonic plague.  By contrast, data previously published in the peer-reviewed scientific journal, Vaccine, demonstrated that a recombinant plague vaccine incorporating the iBioModulator protein, and produced via the iBioLaunchâ„¢ platform in green plants, provided  full protection of non-human primates against aerosolized Y. pestis (pneumonic plague).

An immunomodulator is a substance that alters the immune response.  The iBioModulator platform has been shown in animal models to significantly modify the immune response to a vaccine in two important ways. It increased the strength of the initial immune response to a vaccine antigen (as measured by antibody titer).  It also extended the duration of the immune response. These results demonstrate that the use of the iBioModulator platform may lower vaccine antigen requirements and enable fewer doses to establish prolonged immunity. The ability to improve immune response and provide longer-term protection without the necessity of booster inoculations would add significant value to a vaccine by reducing the overall costs and logistical difficulties of its use while effectively reaching a higher proportion of the target population.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,131.97 +100.83 0.59%
S&P 500 1,998.98 +14.85 0.75%
NASDAQ 4,552.7590 +33.8570 0.75%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs